Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

Pharmacokinetic and Tolerance Study in Healthy Participants: a Single-centre, Randomized, Double-blind, Placebo-controlled Trial

To study the single dose and multi-doses pharmacokinetic characteristics and tolerance of TQ-A3326 in the human body；To study the transformation of TQ-A3326；To study the effect of the food on the pharmacokinetic characteristics of TQ-A3326.

Inclusion Criteria:

• Healthy male or female, age 18 to 60 years, inclusive.
• The body weight of male is not less than 50kg, and female is not less than 45kg. All participants' body mass index (BMI) is between 19~26.
• Adequate blood cell counts, kidney function and liver function.
• Healthy participants should participate in the study voluntarily and sign informed consent.

Exclusion Criteria:

• Subjects with known allergy to the similar products tested.
• Subject is on a special diet (for example subject is vegetarian).
• Medical demographics with evidence of clinically significant deviation from normal medical condition.
• Female subjects who were pregnant or nursing.
• Results of laboratory tests which are clinically significant.
• Acute infection within one week preceding first study drug administration.
• History of drug or alcohol abuse.
• Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
• Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
• ale subjects (or their partner) or female subjects have the unprotective sex behavior or have a planned pregnancy during the trial.